International Journal of Molecular Sciences

Journal Browser

► Journal Browser

Special Issue Editors

Prof. Dr. Montserrat Fernández-Guarino

E-Mail Website
Guest Editor

1. Servicio de Dermatología, Head of Hospitalization and Emergencies in Dermatology, Hospital Ramon y Cajal Madrid, Madrid, Spain
2. Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Madrid, Spain
Interests: cutaneous drug reactions; cutaneous lymphoma; dermatological emergencies; severe dermatological patient; erythroderma; cutaneous vasculitis; graft versus host disease; phototherapy; photobiology
Special Issues, Collections and Topics in MDPI journals

Dr. Belén De la Hoz

E-Mail Website
Guest Editor

Head, Allergy Department, University Ramón y Cajal Hospital, Carretera de Colmenar Km. 9, 100, 28034 Madrid, Spain
Interests: skin disease; dermatology

Dr. Javier Martínez-Botas

E-Mail Website
Guest Editor

Biochemistry-Research Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Carretera de Colmenar Km 9, 28034 Madrid, Spain
Interests: allergy; epitope mapping; microarray; lipid metabolism; cholesterol

Special Issue Information

Dear Colleagues,

Dermatology has undergone profound alterations over the last decade. Today, subspecialisation is needed for the management of inflammatory and complex dermatosis as remaining updated in all fields of dermatology is difficult. Furthermore, new target therapies are emerging along with the discovery of new paths and pathogenic mechanisms. Therefore, interaction with other medical specialties and multidisciplinary management is mandatory.

The new times in dermatology need to be open minded and innovative in hospital practise. Coordination between researchers, diagnosis and possible therapies undoubtedly will advance the work of physicians and benefit patients.

In this Special Issue, entitled “Dermatology: Advances on Pathophysiology and Therapies”, we aim to present this reality and a review of our experience working in coordination, adding a review of the relevant literature. We believe that would be a very useful reference and, thus, we invite physicians working in the field of this novel concept to share their experience and submit their work for publication in the International Journal of Molecular Science. We hope to develop an amazing Issue capable of representing the modern era in medical dermatology.

Prof. Dr. Montserrat Fernández-Guarino
Dr. Belén De la Hoz
Dr. Javier Martínez-Botas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Related Special Issue

Published Papers (2 papers)

Download All Papers

Review

16 pages, 1200 KiB

Open AccessReview

A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation

by Maciej Naumowicz, Stefan Modzelewski, Angelika Macko, Bartosz Łuniewski, Anna Baran and Iwona Flisiak

Int. J. Mol. Sci. 2024, 25(6), 3482; https://doi.org/10.3390/ijms25063482 - 20 Mar 2024

Viewed by 826

Abstract

Necrobiosis lipoidica (NL) is a rare granulomatous disease of a not fully understood etiopathogenesis. Classically, NL is associated with insulin-dependent diabetes mellitus. The disease often fails to respond to conventional treatments and adversely affects patients’ quality of life. First-line medications are usually topical corticosteroids, but patients respond to them with varying degrees of success. Other options include tacrolimus, phototherapy, cyclosporine, fumaric acid esters, and biologics (adalimumab, etanercept, and infliximab). Our review aims to present new therapeutic approaches potentially effective in patients with refractory lesions, describe the presumed etiopathogenesis, and provide diagnostic guidance for clinicians. The review concludes that Janus kinase inhibitors and biologics such as ustekinumab and secukinumab can be used effectively in patients with recalcitrant NL. Another promising treatment option is tapinarof (an aryl hydrocarbon receptor agonist). However, studies on larger groups of patients are still needed to evaluate the effectiveness of different therapeutic options and to define consistent treatment regimens for NL. It is advisable to improve the awareness of physicians of various specialties regarding necrobiosis lipoidica as lesions diagnosed earlier usually have a better response to treatment. Full article

(This article belongs to the Special Issue Dermatology: Advances on Pathophysiology and Therapies 2.0)

► Show Figures

Figure 1

21 pages, 3425 KiB

Open AccessReview

Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review

by Montserrat Fernández-Guarino, Pablo Ortiz, Fernando Gallardo and Mar Llamas-Velasco

Int. J. Mol. Sci. 2024, 25(4), 2203; https://doi.org/10.3390/ijms25042203 - 12 Feb 2024

Viewed by 1323

Abstract

Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. Clinical trials and real-world evidence have underscored its efficacy in advanced CTCLs, including mycosis fungoides and Sézary syndrome; PTCLs; and adult T-cell leukemia/lymphoma (ATLL), showcasing positive outcomes. Notably, the drug has demonstrated significant response rates, disease stability, and extended periods of progression-free survival, suggesting its applicability in cases with multiple treatment lines. Its safety profile is generally manageable, with adverse events (AEs) primarily related to the skin, infusion-related reactions, drug eruptions, autoimmune diseases, and skin disorders. The latter seem to appear as CCR4 can promote the skin-specific homing of lymphocytes, and MOG is directed against this receptor. While combination with immunostimulatory agents like interferon alpha and interleukin 12 has shown promising results, caution is urged when combining with PD1 inhibitors due to the heightened risk of immune-mediated AEs. The introduction of MOG as a systemic treatment implies a significant advancement in managing these diseases, supported by its favorable safety profile and complementary mechanisms. Full article

(This article belongs to the Special Issue Dermatology: Advances on Pathophysiology and Therapies 2.0)

► Show Figures